Zobrazeno 11 - 20
of 20
pro vyhledávání: '"Fitzroy Dawkins"'
Autor:
Andres Forero-Torres, William Jeffery Edenfield, Robert C. Newton, Tycel Phillips, Doug J DeMarini, Swamy Yeleswaram, Rod Ramchandren, Fitzroy Dawkins, Xuejun Chen, Michael S. Wertheim, Martin Gutierrez, Li Zhou
Publikováno v:
Blood. 128:4195-4195
Background: Signaling of PI3Kd has been implicated in proliferation, migration, and function of B cells. PI3Kd inhibitors have demonstrated clinical activity in a number of lymphoid tumor types. INCB050465 is a novel, potent, and highly specific inhi
Autor:
Johanna C. Bendell, Christopher James Walker, Kimberli J. Brill, Jason Clark, Fitzroy Dawkins, Eileen M. O'Reilly
Publikováno v:
Journal of Clinical Oncology. 33:TPS4146-TPS4146
TPS4146 Background: The systemic inflammatory response characteristic of PC is mediated in part by JAK-STAT signaling and may contribute to local tumor growth and disease-related weight loss, decre...
Autor:
Manuel Hidalgo, Eric Van Cutsem, Fitzroy Dawkins, Herbert Hurwitz, William M. Garrett, Kimberli J. Brill, Jason Clark
Publikováno v:
Journal of Clinical Oncology. 33:TPS4147-TPS4147
TPS4147 Background: The systemic inflammatory response observed in PC is a negative prognostic factor and is mediated in part by JAK-STAT signaling. Treatment with the JAK1/JAK2 inhibitor ruxolitin...
Autor:
Svetomir N. Markovic, William Sharfman, Tom Fitch, Susan Geyer, Charles Erlichman, Fitzroy Dawkins, Paula M. Fracasso, D O Patricia LoRusso, William Maples, Alex A. Adjei, Mark Albertini
Publikováno v:
Cancer. 103(12)
BACKGROUND Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti-melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma. METHODS Patients with metasta
Autor:
Scott H. Okuno, Michelle R. Mahoney, Charles Erlichman, Tom Fitch, James A. Stewart, Paula M. Fracasso, Fitzroy Dawkins, William J. Maples, Michael Kraut, David S. Ettinger
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(13)
Purpose Epothilones are a new class of nontaxane tubulin polymerization agents that have activity in taxane-resistant tumors. Epothilone B (BMS-247550) is a semisynthetic analog of the natural product epothilone B. This study was performed to determi
Autor:
Syed, Hasan, Mohamed, Hassan, Luc, Oke, Kimberly, Dinh, Gladys, Onojobi, Fred, Lombardo, Fitzroy, Dawkins, Momodu, Jack
Publikováno v:
Journal of the National Medical Association. 95(12)
Activation of kit-receptor tyrosine kinase occurs in all cases of gastrointestinal stromal tumors, regardless of the mutation status of kit. Imatinib mesylate (STI 571,Gleevec) is a selective inhibitor of certain protein tyrosine kinases. It has been
Publikováno v:
Journal of the National Medical Association. 95(8)
Imatinib mesylate (STI 571, Gleevec) is a potent bcr-abl tyrosine kinase inhibitor. It also inhibits c-kit tyrosine kinase. Imatinib mesylate is active in the treatment of cronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It i
Publikováno v:
Cancer causescontrol : CCC. 13(6)
Compromised breast cancer survival in African American women is well established. Factors associated with poorer survival in this group are not fully elucidated. This analysis examined the influence of alcohol consumption on breast cancer survival in
Autor:
Youn C. Park, Raymond Scott Maul, Bradley J. Monk, Roland Elmar Knoblauch, Trilok V. Parekh, Robert L. Coleman, Fitzroy Dawkins, Marcela G. del Carmen, Thomas J. Herzog
Publikováno v:
Journal of Clinical Oncology. 32:TPS5612-TPS5612
TPS5606 Background: Ovarian cancer (OVC) is the eighth most common cancer among women globally, with approximately 60%–70% of cases being diagnosed at an advanced stage (III or IV). Five-year survi...
Autor:
Thomas J. McIntosh, Yusri Elsayed, Thomas A. Puchalski, Fitzroy Dawkins, Anthony W. Tolcher, Shobha Seetharam, Johann S. de Bono, Shalini Chaturvedi, Kenneth J. Pienta, Chris H. Takimoto
Publikováno v:
Molecular Cancer Therapeutics. 10:A37-A37
Background: Despite the large numbers of antibodies targeting soluble ligands in development in oncology and other therapeutic areas, very few reports have described pharmacodynamic (PD)/ mechanism of action (MOA) biomarkers of free ligand or total (
- [1]
- « Předchozí
- 1
- 2